Amrutanjan Health Care Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AMRUTANJAN BSE: 590006

₹514.75

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #85 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Amrutanjan Health Care Limited (this stock)	1,488	27.6	15.6%	-27.9%	—	79	35	69

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹1,477 Cr

EV / EBITDA

18.6x

EV / Sales

2.89x

Market cap / Sales

2.91x

Earnings yield

3.63%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 107 Cr, up 8.4% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	103	6	4	₹1.5100
March 31, 2026	150	21	16	₹5.6000
Dec. 31, 2025	141	26	19	₹6.7300
Sept. 30, 2025	118	19	14	₹4.8300
June 30, 2025	94	11	8	₹2.8700
March 31, 2025	135	21	15	₹5.2500
Dec. 31, 2024	123	26	19	₹6.6600
Sept. 30, 2024	110	16	12	₹4.0800
June 30, 2024	84	6	5	₹1.6000
March 31, 2024	127	20	14	₹4.7200
Dec. 31, 2023	117	24	17	₹6.0500
Sept. 30, 2023	99	9	7	₹2.3600
June 30, 2023	78	9	7	₹2.4000

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	107	154	145	122	98	140	127	114	88	132	121	103	82
Operating revenue	103	150	141	118	94	135	123	110	84	127	117	99	78
Other income	4	5	4	4	4	5	4	4	4	5	4	4	4
Operating expenses	97	124	116	101	86	118	99	96	80	111	95	92	71
Operating profit	6	26	25	17	8	18	23	14	4	16	22	7	7
Operating profit margin	6.1%	17.1%	17.8%	14.0%	9.0%	13.1%	19.0%	12.4%	4.2%	12.8%	18.4%	6.9%	9.2%
Depreciation	2	2	2	2	2	2	2	2	2	2	2	2	1
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Exceptional items, gain / (loss)	-2	-8	-1	—	—	—	—	—	—	—	—	—	—
Profit before tax	6	21	26	19	11	21	26	16	6	20	24	9	9
Tax	2	5	7	5	3	6	7	4	2	6	6	2	2
Net profit	—	16	19	14	8	15	19	12	5	14	17	7	7
EPS	1.51	5.60	6.73	4.83	2.87	5.25	6.66	4.08	1.60	4.72	6.05	2.36	2.40
Net profit (TTM)	—	58	57	57	55	51	49	48	43	45	44	37	43
EPS (TTM)	18.67	20.03	19.68	19.61	18.86	17.59	17.06	16.45	14.73	15.53	15.16	12.78	14.79

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	503	78	58
March 31, 2025	452	69	51
March 31, 2024	421	62	45
March 31, 2023	380	54	40

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	9.7%	8.6%	520^†	469^†	438^†	394^†	421^†	344^†	270^†	261^†	231^†	225^†
Operating revenue	9.8%	8.6%	503	452	421	380	406^†	333^†	261^†	254^†	226^†	219^†
Other income	—	—	18^†	18^†	16^†	15^†	15^†	11^†	8^†	7^†	6^†	6^†
Operating expenses	—	—	427^†	394^†	369^†	335^†	326^†	258^†	231^†	—	—	190^†
Operating profit	19.5%	0.2%	76^†	58^†	52^†	44^†	79^†	75^†	31^†	—	—	29^†
Operating profit margin	—	—	15.1%^†	12.9%^†	12.3%^†	11.7%^†	19.6%^†	22.5%^†	11.7%^†	—	—	13.2%^†
Depreciation	—	—	6^†	7^†	6^†	5^†	4^†	4^†	4^†	—	—	2^†
Interest	—	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	—	0^†	0^†
Exceptional items, gain / (loss)	—	—	-9^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	2^†	3^†
Profit before tax	13.2%	-1.0%	78	69	62	54	91^†	82^†	34^†	35^†	32^†	35^†
Tax	—	—	20^†	18^†	17^†	14^†	23^†	21^†	9^†	10^†	13^†	12^†
Net profit	13.3%	-1.1%	58	51	45	40	67^†	61^†	25^†	—	—	23^†
EPS	13.7%	-0.9%	20.03^†	17.59^†	15.53^†	13.64^†	23.05^†	20.94^†	8.58^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	15.1%^†	12.9%^†	12.3%^†	11.7%^†	19.6%^†	22.5%^†	11.7%^†	—	—	13.2%^†
EBIT margin	15.5%^†	15.3%^†	14.7%^†	14.2%^†	22.4%^†	24.8%^†	13.3%^†	—	14.2%^†	16.1%^†
PBT margin	15.5%	15.3%	14.7%	14.1%	22.3%^†	24.6%^†	13.2%^†	13.8%^†	14.1%^†	16.0%^†
Net margin	11.5%	11.3%	10.7%	10.5%	16.6%^†	18.4%^†	9.6%^†	—	—	10.4%^†
Interest coverage	400.42x^†	316.39x^†	396.32x^†	697.69x^†	187.99x^†	164.81x^†	156.90x^†	—	136.33x^†	285.21x^†
Dividend payout	—	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—	—
Current ratio	2.31x	3.44x	—	—	—	—	—	—	—	—
Quick ratio	2.02x	3.11x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.00x	—	—	—	—	—	—	—	—
Return on equity	15.6%	15.6%	—	—	—	—	—	—	—	—
Return on assets	11.4%	12.1%	—	—	—	—	—	—	—	—
Return on capital employed	20.4%^†	20.6%^†	—	—	—	—	—	—	—	—
Asset turnover	0.99x	1.07x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	36	-21	-14	55	-19
March 31, 2025	51	-31	-13	36	15
March 31, 2024	28	19	-48	7	21
March 31, 2023	19	-2	-14	9	10
March 31, 2022	53	-36	-18	23	30

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	509	370	367	0	0	292	126	11	50	37
March 31, 2025	421	327	324	0	0	291	85	10	48	27
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.